Summary
PROJECT SUMMARY/ABSTRACT Asthma is a leading cause of morbidity in the US and worldwide, affecting almost 10% of the US population. Individuals with severe asthma, who are uncontrolled on conventional therapy, account for a disproportionate share of asthma-related morbidity and mortality. For these patients, the advent of multiple monoclonal antibodies “biologics” has provided additional therapeutic options to improve outcomes in this potentially fatal disease. While these biologics have helped to improved outcomes in many patients with asthma, there is considerable uncertainty on the optimal
